Welcome to our dedicated page for Semler Scientific SEC filings (Ticker: SMLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Semler Scientific, Inc. filings document its common-stock status, material events and public-company reporting history. Recent regulatory records include Form 25 disclosure for removal of the common stock from Nasdaq listing and registration, and Form 15 certification covering termination or suspension of Exchange Act reporting obligations for the class of securities.
The company's 8-K filings cover material agreements, shareholder voting matters, governance items, capital-structure disclosures and operating and financial results. Filing categories also address risk factors and clinical or regulatory matters tied to Semler Scientific's healthcare technology activities, alongside disclosures related to its Bitcoin treasury strategy.
Strive, Inc. filed a Form 425 communication about its proposed business combination with Semler Scientific, Inc. The notice states Strive intends to file a Form S-4 to register Class A common stock to be issued in connection with the transaction, which will include an information statement/proxy statement/prospectus.
A definitive proxy will be sent to Semler Scientific stockholders to seek their approval. The communication includes cautionary forward-looking statements and a standard “no offer or solicitation” disclaimer, directing investors to future SEC filings for full details.
Strive, Inc. posted a communication regarding its proposed business combination with Semler Scientific, Inc. (SMLR). The notice includes a forward‑looking statements disclaimer and outlines next steps for the transaction process.
Strive intends to file a Form S-4 to register Class A common stock to be issued in the transaction, which will include an information statement/proxy statement/prospectus. Semler Scientific stockholders will receive proxy materials to vote on the proposed transaction. This communication is not an offer to sell or solicit the purchase of securities.
Strive, Inc. announced a proposed business combination with Semler Scientific and outlined next steps in the regulatory process. Strive intends to file an S-4 registration statement to register Class A common stock to be issued in the transaction, which will include an information statement, proxy statement for Semler Scientific stockholders, and a prospectus.
A definitive proxy/prospectus will be sent to Semler Scientific stockholders to seek approval of the proposed transaction. The communication includes a standard caution about forward-looking statements and directs investors to review the S-4 and related materials when available on the SEC’s website and the companies’ investor sites.
Strive, Inc. filed a Rule 425 communication regarding its proposed business combination with Semler Scientific, Inc.
Strive plans to file a Form S-4 to register Class A common stock to be issued in the transaction. A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval. The communication includes a comprehensive forward‑looking statements caution.
Transaction materials will be available on the SEC’s website and the companies’ investor relations sites. The notice states it is not an offer or solicitation to buy or sell securities.
Strive, Inc. shared a Rule 425 communication about its proposed business combination with Semler Scientific (SMLR). The message, reposted on X by Strive’s CMO on October 24, 2025, includes a standard caution that forward‑looking statements involve risks and uncertainties. Strive plans to file a Form S-4 to register Class A common stock to be issued in the transaction, which will include an information statement/proxy statement/prospectus. Semler stockholders will receive materials to consider the proposal, and related documents will be available on the SEC’s website and the companies’ investor pages.
Semler Scientific (SMLR) announced a leadership change. On October 16, 2025, Renae Cormier resigned as Chief Financial Officer, principal financial officer, and principal accounting officer, effective October 30, 2025, to pursue another opportunity.
The board appointed President and CEO Dr. Douglas Murphy‑Chutorian to serve as interim Chief Financial Officer and as principal financial officer and principal accounting officer effective October 30, 2025. He will receive no additional compensation for these interim duties. Biographical information for Dr. Murphy‑Chutorian is incorporated by reference from the company’s July 17, 2025 proxy statement.
Strive, Inc. and Semler Scientific plan an all‑stock merger to combine as a Bitcoin Treasury company. In a Yahoo Finance interview included here, the discussion highlights a combined balance sheet with more than 10,000 Bitcoin and the goal of lowering operating costs through scale while pursuing strategies designed to outperform Bitcoin over time.
Strive’s CEO also described expanding Semler’s operating focus toward preventative healthcare, guided by experienced board members. To move forward, Strive will file a Form S‑4 registering the Class A common stock to be issued, and Semler stockholders will receive a proxy to vote on the proposed transaction. Investors are directed to review the forthcoming Registration Statement and related materials when available.
Semler Scientific filed an 8-K reporting a material event related to its pending merger and a financing arrangement. The filing lists potential risks that could prevent the merger from closing, including termination rights under the merger agreement, unmet closing conditions, litigation, failure to realize anticipated benefits (including risks from Bitcoin treasury strategies and digital assets), integration challenges, higher-than-expected transaction costs, management distraction, dilution from additional Class A share issuances, adverse customer or employee reactions, and share-price volatility. The filing also identifies an exhibit: a Master Loan Agreement dated April 15, 2025 among Coinbase Credit, Inc., Coinbase, Inc. and Semler Scientific, Inc., which appears to be a material financing document disclosed with the 8-K.
Semler Scientific, Inc. (SMLR) filed a Form 8-K reporting a material event related to a proposed transaction with Strive and Strive’s affiliate Semler Sci. The filing lists risks that could affect completion and outcomes of the merger agreement, including termination rights, failure to satisfy closing conditions, litigation, integration challenges, higher than expected transaction costs, diversion of management attention, dilution from issuing Class A common stock, adverse customer or employee reactions, and exposure to risks from Bitcoin treasury strategies and digital assets. The filing includes two exhibits: supplemental information dated September 22, 2025, and supplemental unaudited pro forma combined financial information.
Semler Scientific, Inc. (SMLR) disclosed a signed Agreement and Plan of Merger dated September 22, 2025, with Strive, Inc., and identified a range of transaction risks. The filing lists events that could let either party terminate the merger, and warns the deal may not close on schedule or at all if closing conditions are unmet. The company highlights potential integration challenges, higher-than-expected transaction costs, management distraction, customer or employee reactions, dilution from issuing additional Class A stock, share-price volatility, and specific risks tied to Bitcoin treasury strategies and digital-asset exposures. The filing is signed by CFO Renae Cormier.